JP2009515823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515823A5 JP2009515823A5 JP2008535681A JP2008535681A JP2009515823A5 JP 2009515823 A5 JP2009515823 A5 JP 2009515823A5 JP 2008535681 A JP2008535681 A JP 2008535681A JP 2008535681 A JP2008535681 A JP 2008535681A JP 2009515823 A5 JP2009515823 A5 JP 2009515823A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- tlr
- oligonucleotide
- composition
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000002689 Toll-like receptor Human genes 0.000 claims description 28
- 108020000411 Toll-like receptor Proteins 0.000 claims description 28
- 108091034117 Oligonucleotide Proteins 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 16
- 239000000556 agonist Substances 0.000 claims description 13
- 239000005557 antagonist Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 230000003308 immunostimulating effect Effects 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 5
- 230000002519 immonomodulatory effect Effects 0.000 claims description 4
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 238000007385 chemical modification Methods 0.000 claims description 3
- 229940029575 guanosine Drugs 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 12
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims 2
- 208000037883 airway inflammation Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000002213 purine nucleotide Chemical class 0.000 claims 2
- 150000003212 purines Chemical class 0.000 claims 2
- 239000002719 pyrimidine nucleotide Chemical class 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108010041986 DNA Vaccines Proteins 0.000 claims 1
- 229940021995 DNA vaccine Drugs 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 229960004784 allergens Drugs 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- -1 antibodies Substances 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000007933 dermal patch Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000002324 mouth wash Substances 0.000 claims 1
- 229940051866 mouthwash Drugs 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical group C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000012423 response to bacterium Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72603405P | 2005-10-12 | 2005-10-12 | |
| US60/726,034 | 2005-10-12 | ||
| US78424306P | 2006-03-21 | 2006-03-21 | |
| US60/784,243 | 2006-03-21 | ||
| US82544006P | 2006-09-13 | 2006-09-13 | |
| US60/825,440 | 2006-09-13 | ||
| PCT/US2006/039954 WO2007047396A2 (en) | 2005-10-12 | 2006-10-12 | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515823A JP2009515823A (ja) | 2009-04-16 |
| JP2009515823A5 true JP2009515823A5 (enExample) | 2018-08-30 |
| JP6406793B2 JP6406793B2 (ja) | 2018-10-17 |
Family
ID=37963095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008535681A Expired - Fee Related JP6406793B2 (ja) | 2005-10-12 | 2006-10-12 | トール様受容体に基づく免疫反応を調整する免疫調節ヌクレオチド（ｉｒｏ）化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US8357665B2 (enExample) |
| EP (4) | EP2343307B1 (enExample) |
| JP (1) | JP6406793B2 (enExample) |
| KR (1) | KR101455081B1 (enExample) |
| CN (2) | CN101287742B (enExample) |
| AU (1) | AU2006304205C1 (enExample) |
| CA (1) | CA2624755C (enExample) |
| ES (2) | ES2542989T3 (enExample) |
| WO (1) | WO2007047396A2 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
| ES2542989T3 (es) | 2005-10-12 | 2015-08-13 | Idera Pharmaceuticals, Inc. | Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll |
| JP2010510227A (ja) | 2006-11-20 | 2010-04-02 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 痛みおよび痒みの治療方法、組成物およびキット |
| CA2693266C (en) * | 2007-08-01 | 2015-06-30 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
| US8853375B2 (en) | 2007-08-15 | 2014-10-07 | Idera Pharmaceuticals, Inc. | Toll like receptor modulators |
| CN102083984A (zh) * | 2007-12-26 | 2011-06-01 | 森托科尔奥索生物科技公司 | 食蟹猴Toll样受体3 |
| WO2009154610A1 (en) * | 2008-06-17 | 2009-12-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| CN101643496B (zh) * | 2008-08-07 | 2015-09-09 | 长春华普生物技术有限公司 | 一种具有免疫抑制功能的寡核苷酸 |
| WO2010039615A2 (en) * | 2008-10-03 | 2010-04-08 | Centocor Ortho Biotech Inc. | Papio cynocephalus toll-like receptor 3 |
| KR20110071108A (ko) * | 2008-10-06 | 2011-06-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 고콜레스테롤혈증 및 고지혈증 및 이에 관련된 질병의 예방 및 치료에서 톨-유사 수용체의 저해제의 용도 |
| CA2742531A1 (en) | 2008-11-04 | 2010-05-14 | Idera Pharmaceuticals, Inc. | Modulation of toll-like receptor 5 expression by antisense oligonucleotides |
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| BRPI1008063A2 (pt) * | 2009-01-30 | 2015-08-25 | Idera Pharmaceuticals Inc | Agonistas sinteticas de tlr9 |
| MX2011010050A (es) | 2009-03-25 | 2011-12-14 | Univ Texas | Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos. |
| US8987221B2 (en) * | 2009-06-01 | 2015-03-24 | Idera Pharmaceuticals, Inc. | Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9 |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| EP2451974A2 (en) | 2009-07-08 | 2012-05-16 | Idera Pharmaceuticals, Inc. | Oligonucleotide-based compounds as inhibitors of toll-like receptors |
| JP6205133B2 (ja) | 2009-07-10 | 2017-09-27 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
| DE102009034779A1 (de) | 2009-07-25 | 2011-02-03 | Emc Microcollections Gmbh | Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen |
| HRP20150566T1 (hr) * | 2009-08-27 | 2015-07-17 | Idera Pharmaceuticals, Inc. | Kompozicija za inhibiciju ekspresije gena i njegova upotreba |
| US20120301463A1 (en) | 2009-09-30 | 2012-11-29 | President And Fellows Of Harvard College | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products |
| BR112012032240A2 (pt) | 2010-06-16 | 2019-09-24 | Dynavax Technologies Corporation | método de tratamento utilizando inibidores tlr7 e/ou tlr9 |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| US8486908B2 (en) * | 2010-11-19 | 2013-07-16 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| GB201021867D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| CA2879066C (en) * | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| WO2014085154A1 (en) | 2012-11-27 | 2014-06-05 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| WO2014110081A1 (en) * | 2013-01-08 | 2014-07-17 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| US9688993B2 (en) | 2015-02-13 | 2017-06-27 | Idera Pharmaceuticals, Inc. | Toll-like receptor 9 antagonist and methods of use thereof |
| CN104807994B (zh) * | 2015-04-29 | 2016-08-24 | 大连理工大学 | 一种基于脱碱基位点的免标记凝血酶检测方法 |
| KR101745520B1 (ko) * | 2015-05-29 | 2017-06-12 | 아주대학교산학협력단 | 신규한 tlr4 길항제 |
| RU2018107695A (ru) | 2015-08-03 | 2019-09-05 | Президент Энд Феллоуз Оф Гарвард Колледж | Заряженные блокаторы ионных каналов и способы их применения |
| LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
| GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
| EP3436066A1 (en) | 2016-04-01 | 2019-02-06 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
| EP3468605A4 (en) | 2016-06-08 | 2020-01-08 | President and Fellows of Harvard College | MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS |
| AU2017364964B2 (en) | 2016-11-23 | 2023-04-20 | Berlin Cures GmbH | Aptamers for use in inhibition and/or suppression of TLR9 activation |
| EP3690030A4 (en) | 2017-09-28 | 2021-06-23 | Industry-Academic Cooperation Foundation, Yonsei University | PROCESS FOR THE PRODUCTION OF SUPPRESSIVE CELLS OF MYELOID ORIGIN, SUPPRESSIVE CELLS OF MYELOID ORIGIN THUS PRODUCED AND THEIR USES |
| JP2021502381A (ja) | 2017-11-08 | 2021-01-28 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ウイルスベクター誘発性炎症反応を阻害するための組成物および方法 |
| EP3752194A4 (en) | 2018-02-13 | 2022-03-16 | Checkmate Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY |
| EP3775218A1 (en) | 2018-04-09 | 2021-02-17 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
| US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| JP7692834B2 (ja) | 2019-03-11 | 2025-06-16 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| BR112021017772A2 (pt) | 2019-03-11 | 2021-11-16 | Nocion Therapeutics Inc | Bloqueadores de canais de íons carregados e métodos para uso |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| BR112021017809A2 (pt) | 2019-03-11 | 2021-11-23 | Nocion Therapeutics Inc | Bloqueadores de canais iônicos substituídos por éster e métodos para uso |
| EP3939987A4 (en) * | 2019-03-13 | 2023-02-08 | Cartiprime Co., Ltd. | OLIGONUCLEOTIDE WITH ANTI-INFLAMMATORY ACTIVITY |
| AU2020380118A1 (en) | 2019-11-06 | 2022-05-19 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| JP7513713B2 (ja) | 2019-11-06 | 2024-07-09 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| BR112022017801A2 (pt) | 2020-03-11 | 2022-10-25 | Nocion Therapeutics Inc | Bloqueadores de canais de íons carregados e métodos para uso |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CN114099535B (zh) * | 2020-12-10 | 2023-01-03 | 南京吉迈生物技术有限公司 | Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物 |
| AU2021401085A1 (en) * | 2020-12-16 | 2023-07-06 | Dynavax Technologies Corporation | Method for quantifying cpg-containing oligonucleotides in formulations comprising alum |
| WO2024137496A1 (en) | 2022-12-19 | 2024-06-27 | Six Therapeutics Inc. | Compositions and methods of using cpg oligonucleotides |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US97719A (en) * | 1869-12-07 | E-benez ee sperry | ||
| US239733A (en) * | 1881-04-05 | William w | ||
| AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| WO2001012804A2 (en) * | 1999-08-13 | 2001-02-22 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| US6899891B2 (en) | 1999-12-16 | 2005-05-31 | Harry J. Siskind | Nutritional composition, methods of producing said composition and methods of using said composition |
| US6815429B2 (en) | 2000-01-26 | 2004-11-09 | Hybridon, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| PT1278761E (pt) * | 2000-05-01 | 2005-08-31 | Hybridon Inc | Modulacao da estimulacao imunitaria mediada por oligonucleotidos de cpg, por modificacao posicional de nucleosidos |
| US7105495B2 (en) | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| SE0201701D0 (sv) * | 2002-06-05 | 2002-06-05 | Gotovax Ab | Treatment of epithelial tumors and infections |
| AU2003243409A1 (en) | 2002-06-05 | 2003-12-22 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
| EP1393745A1 (en) * | 2002-07-29 | 2004-03-03 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends |
| WO2004094671A2 (en) | 2003-04-22 | 2004-11-04 | Coley Pharmaceutical Gmbh | Methods and products for identification and assessment of tlr ligands |
| JP2006528697A (ja) * | 2003-05-16 | 2006-12-21 | イデラ ファーマシューティカルズ インコーポレイテッド | イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置 |
| MXPA05013922A (es) * | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
| KR101126030B1 (ko) * | 2003-07-15 | 2012-03-19 | 이데라 파마슈티칼즈, 인코포레이티드 | 사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법 |
| US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| GB0329146D0 (en) | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
| SI1794174T1 (sl) | 2004-09-01 | 2012-09-28 | Dynavax Tech Corp | Postopki in sestavki za inhibiranje prirojenih imunskih odzivov in avtoimunosti |
| EP1819364A4 (en) | 2004-12-08 | 2010-12-29 | 3M Innovative Properties Co | COMPOSITIONS, IMMUNOMODULATORY COMBINATIONS AND ASSOCIATED METHODS |
| WO2006066003A2 (en) | 2004-12-17 | 2006-06-22 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
| AU2006294528A1 (en) | 2005-09-27 | 2007-04-05 | Coley Pharmaceutical Gmbh | Modulation of TLR-mediated immune responses using adaptor oligonucleotides |
| US8426375B2 (en) | 2005-10-12 | 2013-04-23 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US8383598B2 (en) | 2005-10-12 | 2013-02-26 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| ES2542989T3 (es) | 2005-10-12 | 2015-08-13 | Idera Pharmaceuticals, Inc. | Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll |
| US8399423B2 (en) | 2005-10-12 | 2013-03-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US8377898B2 (en) | 2006-10-12 | 2013-02-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| US8853375B2 (en) | 2007-08-15 | 2014-10-07 | Idera Pharmaceuticals, Inc. | Toll like receptor modulators |
| CA2703931C (en) | 2007-10-26 | 2016-08-16 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
| US20090131512A1 (en) | 2007-10-31 | 2009-05-21 | Dynavax Technologies Corp. | Inhibition of type I in IFN production |
-
2006
- 2006-10-12 ES ES06825856.5T patent/ES2542989T3/es active Active
- 2006-10-12 EP EP10013989.8A patent/EP2343307B1/en not_active Not-in-force
- 2006-10-12 US US11/549,048 patent/US8357665B2/en not_active Expired - Fee Related
- 2006-10-12 ES ES10013989.8T patent/ES2544877T3/es active Active
- 2006-10-12 CN CN200680038283.2A patent/CN101287742B/zh not_active Expired - Fee Related
- 2006-10-12 CA CA2624755A patent/CA2624755C/en active Active
- 2006-10-12 AU AU2006304205A patent/AU2006304205C1/en not_active Ceased
- 2006-10-12 CN CN201410469705.8A patent/CN104278037B/zh not_active Expired - Fee Related
- 2006-10-12 JP JP2008535681A patent/JP6406793B2/ja not_active Expired - Fee Related
- 2006-10-12 EP EP11000806A patent/EP2341059A1/en not_active Withdrawn
- 2006-10-12 EP EP15168723.3A patent/EP2982679A1/en not_active Withdrawn
- 2006-10-12 KR KR1020087011265A patent/KR101455081B1/ko not_active Expired - Fee Related
- 2006-10-12 EP EP06825856.5A patent/EP1934239B8/en not_active Not-in-force
- 2006-10-12 WO PCT/US2006/039954 patent/WO2007047396A2/en not_active Ceased
-
2012
- 2012-12-31 US US13/731,492 patent/US9206430B2/en not_active Expired - Fee Related
-
2015
- 2015-12-01 US US14/955,418 patent/US9453228B2/en not_active Expired - Fee Related
-
2016
- 2016-08-16 US US15/238,074 patent/US20170145417A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515823A5 (enExample) | ||
| CN106535876B (zh) | 免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用 | |
| JP6406793B2 (ja) | トール様受容体に基づく免疫反応を調整する免疫調節ヌクレオチド（ｉｒｏ）化合物 | |
| US10144933B2 (en) | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator | |
| US10322173B2 (en) | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent | |
| US9617547B2 (en) | Chiral nucleic acid adjuvant | |
| US20070202575A1 (en) | Oligodeoxynucleotide and its use to induce an immune response | |
| JP7419268B2 (ja) | 変異ｋｒａｓ配列及び脂質を含む化合物並びにその使用 | |
| EP3758712B1 (en) | Cpg amphiphiles and uses thereof | |
| US20060094680A1 (en) | Immunostimulatory oligonucleotide multimers | |
| US9260719B2 (en) | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | |
| MX2011001317A (es) | Modulacion de la expresion del receptor de tipo toll 3 por medio de oligonucleotidos antisentido. | |
| US20070093439A1 (en) | Short immunomodulatory oligonucleotides | |
| EP3509700A1 (en) | Pd-1 specific aptamers | |
| MX2011001315A (es) | Modulacion de la expresion de los receptores del tipo toll 7 mediante oligonucleotidos antisentido. | |
| TW202449155A (zh) | 用於肌肉萎縮症之外顯子跳躍寡聚物 | |
| HK40045177B (en) | Cpg amphiphiles and uses thereof | |
| HK40045177A (en) | Cpg amphiphiles and uses thereof | |
| HK40043266A (en) | Cpg amphiphiles and uses thereof | |
| CN101426370A (zh) | 免疫刺激性寡核苷酸多聚体 |